BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its commitment to innovation in blood disorders and hematologic oncology at the 57th American Society of Hematology (ASH) Annual Meeting, beginning today through Dec. 8, in Orlando, Florida.
